Generic Name and Formulations:
Ergotamine tartrate 1mg, caffeine 100mg; tabs.
Various generic manufacturers
Migraine, migraine variants, cluster headaches.
2 tablets at onset of attack, then 1 tablet every ½ hour if needed; max 6 tabs/attack, 10 tabs/week.
Peripheral vascular disease. Coronary heart disease. Hypertension. Hepatic or renal dysfunction. Sepsis. Concomitant potent CYP3A4 inhibitors (eg, ritonavir, nelfinavir, indinavir, erythromycin, clarithromycin, troleandomycin, ketoconazole, itraconazole) or other vasoconstrictors. Labor & delivery. Pregnancy (Cat.X).
Monitor for ergotism; do not exceed recommended dose. Nursing mothers: not recommended.
See Contraindications. Potentiated by CYP3A4 inhibitors (eg, protease inhibitors, macrolides, azole antifungals, saquinavir, nefazodone, fluoxetine, fluvoxamine, grapefruit juice, zileuton), propranolol, nicotine. Severe hypertension with sympathomimetics.
Vasoconstrictive complications or ergotism (eg, ischemia, cold extremities, vasospasm, ECG changes, hyper- or hypotension, numbness, gangrene, dizziness), precordial or muscle pain, tachycardia, bradycardia, nausea, vomiting, local edema, itching; rarely: retroperitoneal and pleuropulmonary fibrosis, cardiac valve fibrosis (chronic use).
Supps formerly known under the brand names Cafergot, Migergot.
Join MIMS Learning now to manage all your CPD and notes in one place!
Already a MIMS Learning member?Sign In Now »
This red flags article explains signs and symptoms of potentially serious pathology in patients presenting...
This article by Dr Tillmann Jacobi covers the possible red flag symptoms to consider when a patient...
Dr Suneeta Kochhar provides an overview of red flag symptoms in patients presenting with headaches...
In this article, Dr David Brass and Dr Neil Rajan discuss the risk factors for BCC, making the diagnosis...
This article by Dr Rajiv Sankaranarayanan covers the diagnosis and management of cardiomyopathy. Key...
Dr Benjamin Simpson provides an in-depth overview of Parkinson’s disease, including information on risk...